Merck is also giving Intrexon $25 million in cash to help get the CAR-T programmes going, and says the handover will allow it to focus on its other R&D activities but still maintain an interest in ...

Merck ( MRK 0.53%) stock has been a longtime winner for investors, returning 72% in the past five years. A major factor in ...

The Committee for Medicinal Products for Human Use recommends marketing approval for Merck's Keytruda for treating two types of gynecologic cancers. The FDA approves MRK's Keytruda for first-line ...

Barron's market reporter Jacob Sonenshine breaks down the market as the Fed meeting kicks off and spotlights pharmaceutical company Merck.

Merck's business is growing, but the stock's gains have been modest this year. The drug manufacturer remains heavily reliant on Keytruda, which accounts for nearly half of its revenue. Merck has ...

Last week, students and family members from Red Fox Community School participated in their annual Mountain Day hike at Merck ...

What’s next for Akeso and Summit Therapeutics after their cancer immunotherapy outperformed Merck’s Keytruda in a large Phase 3 clinical trial? Who’s the iconoclastic outsider behind Summit ...

A Merck & Co. effort to move its PD-1 behemoth Keytruda into early treatment of lung cancer has reached a dead end, along with another bid to expand into a type of early-stage skin cancer.

Merck’s cancer immunotherapy Keytruda is the drug industry’s biggest blockbuster, bringing in $25 billion in sales last year. For years drug companies have sought to beat the therapy to no avail.

In an email, the company pointed out that the majority of patients in LITESPARK-005 received Welireg as their third or fourth-line treatment (87.4%) after being treated with PD-1/L1 inhibitor and ...

Merck (NYSE: MRK) is a top pharmaceutical company coming off a good quarter that shows it is growing its top and bottom lines. Even with that growth, the stock still trades at a fairly modest ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...